Literature DB >> 20012858

Gut barrier disruption by an enteric bacterial pathogen accelerates insulitis in NOD mice.

A S Lee1, D L Gibson, Y Zhang, H P Sham, B A Vallance, J P Dutz.   

Abstract

AIMS/HYPOTHESIS: Increased exposure to enteric microbes as a result of intestinal barrier disruption is thought to contribute to the development of several intestinal inflammatory diseases; however, it less clear whether such exposure modulates the development of extra-intestinal inflammatory and autoimmune diseases. The goal of this study was to examine the potential role of pathogenic enteric microbes and intestinal barrier dysfunction in the pathogenesis of type 1 diabetes.
METHODS: Using NOD mice, we assessed: (1) intrinsic barrier function in mice at different ages by measuring serum levels of FITC-labelled dextran; and (2) the impact on insulitis development of infection by strains of an enteric bacterial pathogen (Citrobacter rodentium) either capable (wild-type) or incapable (lacking Escherichia coli secreted protein F virulence factor owing to deletion of the gene [DeltaespF]) of causing intestinal epithelial barrier disruption.
RESULTS: Here we demonstrate that prediabetic (12-week-old) NOD mice display increased intestinal permeability compared with non-obese diabetes-resistant and C57BL/6 mice. We also found that young (4-week-old) NOD mice infected with wild-type C. rodentium exhibited accelerated development of insulitis in concert with infection-induced barrier disruption. In contrast, insulitis development was not altered in NOD mice infected with the non-barrier-disrupting DeltaespF strain. Moreover, C. rodentium-infected NOD mice demonstrated increased activation and proliferation of pancreatic-draining lymph node T cells, including diabetogenic CD8(+) T cells, compared with uninfected NOD mice. CONCLUSIONS/
INTERPRETATION: This is the first demonstration that a loss of intestinal barrier integrity caused by an enteric bacterial pathogen results in the activation of diabetogenic CD8(+) T cells and modulates insulitis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20012858     DOI: 10.1007/s00125-009-1626-y

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  42 in total

1.  Increased intestinal permeability as a cause of fluctuating postprandial blood glucose levels in Type 1 diabetic patients.

Authors:  T Damci; I Nuhoglu; G Devranoglu; Z Osar; M Demir; H Ilkova
Journal:  Eur J Clin Invest       Date:  2003-05       Impact factor: 4.686

2.  Endocrine self and gut non-self intersect in the pancreatic lymph nodes.

Authors:  Shannon J Turley; Je-Wook Lee; Nick Dutton-Swain; Diane Mathis; Christophe Benoist
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-29       Impact factor: 11.205

Review 3.  Coxsackievirus infection as an environmental factor in the etiology of type 1 diabetes.

Authors:  Martin J Richer; Marc S Horwitz
Journal:  Autoimmun Rev       Date:  2009-02-11       Impact factor: 9.754

4.  Role of the intestinal tight junction modulator zonulin in the pathogenesis of type I diabetes in BB diabetic-prone rats.

Authors:  Tammara Watts; Irene Berti; Anna Sapone; Tania Gerarduzzi; Tarcisio Not; Ronald Zielke; Alessio Fasano
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-14       Impact factor: 11.205

5.  Salmonella typhimurium infection in nonobese diabetic mice generates immunomodulatory dendritic cells able to prevent type 1 diabetes.

Authors:  Tim Raine; Paola Zaccone; Pietro Mastroeni; Anne Cooke
Journal:  J Immunol       Date:  2006-08-15       Impact factor: 5.422

Review 6.  Molecular pathogenesis of Citrobacter rodentium and transmissible murine colonic hyperplasia.

Authors:  S A Luperchio; D B Schauer
Journal:  Microbes Infect       Date:  2001-04       Impact factor: 2.700

7.  Diabetogenic T cells are primed both in pancreatic and gut-associated lymph nodes in NOD mice.

Authors:  Ilkka Jaakkola; Sirpa Jalkanen; Arno Hänninen
Journal:  Eur J Immunol       Date:  2003-12       Impact factor: 5.532

8.  Glucagon-like peptide-2 reduces intestinal permeability but does not modify the onset of type 1 diabetes in the nonobese diabetic mouse.

Authors:  Irene Hadjiyanni; Kunmin Karen Li; Daniel J Drucker
Journal:  Endocrinology       Date:  2008-10-09       Impact factor: 4.736

9.  Intestinal permeability to mannitol and lactulose in children with type 1 diabetes with the HLA-DQB1*02 allele.

Authors:  Mikael Kuitunen; Tero Saukkonen; Jorma Ilonen; Hans K Akerblom; Erkki Savilahti
Journal:  Autoimmunity       Date:  2002-08       Impact factor: 2.815

10.  Innate immunity and intestinal microbiota in the development of Type 1 diabetes.

Authors:  Li Wen; Ruth E Ley; Pavel Yu Volchkov; Peter B Stranges; Lia Avanesyan; Austin C Stonebraker; Changyun Hu; F Susan Wong; Gregory L Szot; Jeffrey A Bluestone; Jeffrey I Gordon; Alexander V Chervonsky
Journal:  Nature       Date:  2008-09-21       Impact factor: 49.962

View more
  58 in total

1.  Targeting gut microbiota and barrier function with prebiotics to alleviate autoimmune manifestations in NOD mice.

Authors:  Camilla H F Hansen; Christian S Larsen; Henriette O Petersson; Line F Zachariassen; Andreas Vegge; Charlotte Lauridsen; Witold Kot; Łukasz Krych; Dennis S Nielsen; Axel K Hansen
Journal:  Diabetologia       Date:  2019-05-28       Impact factor: 10.122

2.  Prolonged antibiotic treatment induces a diabetogenic intestinal microbiome that accelerates diabetes in NOD mice.

Authors:  Kirsty Brown; Artem Godovannyi; Caixia Ma; YiQun Zhang; Zahra Ahmadi-Vand; Chaunbin Dai; Monika A Gorzelak; YeeKwan Chan; Justin M Chan; Arion Lochner; Jan P Dutz; Bruce A Vallance; Deanna L Gibson
Journal:  ISME J       Date:  2015-08-14       Impact factor: 10.302

Review 3.  Type 1 diabetes and celiac disease: clinical overlap and new insights into disease pathogenesis.

Authors:  Aaron Cohn; Anthony M Sofia; Sonia S Kupfer
Journal:  Curr Diab Rep       Date:  2014-08       Impact factor: 4.810

Review 4.  The crucial role of early-life gut microbiota in the development of type 1 diabetes.

Authors:  He Zhou; Lin Sun; Siwen Zhang; Xue Zhao; Xiaokun Gang; Guixia Wang
Journal:  Acta Diabetol       Date:  2020-07-25       Impact factor: 4.280

Review 5.  The intestinal epithelial barrier: a therapeutic target?

Authors:  Matthew A Odenwald; Jerrold R Turner
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-11-16       Impact factor: 46.802

Review 6.  Does the gut microbiota have a role in type 1 diabetes? Early evidence from humans and animal models of the disease.

Authors:  M A Atkinson; A Chervonsky
Journal:  Diabetologia       Date:  2012-08-09       Impact factor: 10.122

7.  Naturally transmitted segmented filamentous bacteria segregate with diabetes protection in nonobese diabetic mice.

Authors:  Martin A Kriegel; Esen Sefik; Jonathan A Hill; Hsin-Jung Wu; Christophe Benoist; Diane Mathis
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-27       Impact factor: 11.205

8.  Human gut microbiota transferred to germ-free NOD mice modulate the progression towards type 1 diabetes regardless of the pace of beta cell function loss in the donor.

Authors:  Vit Neuman; Ondrej Cinek; David P Funda; Tomas Hudcovic; Jaroslav Golias; Lenka Kramna; Lenka Petruzelkova; Stepanka Pruhova; Zdenek Sumnik
Journal:  Diabetologia       Date:  2019-04-25       Impact factor: 10.122

9.  Maternal obesity induces gut inflammation and impairs gut epithelial barrier function in nonobese diabetic mice.

Authors:  Yansong Xue; Hui Wang; Min Du; Mei-Jun Zhu
Journal:  J Nutr Biochem       Date:  2014-04-01       Impact factor: 6.048

10.  Restoration of impaired intestinal barrier function by the hydrolysed casein diet contributes to the prevention of type 1 diabetes in the diabetes-prone BioBreeding rat.

Authors:  J T J Visser; K Lammers; A Hoogendijk; M W Boer; S Brugman; S Beijer-Liefers; A Zandvoort; H Harmsen; G Welling; F Stellaard; N A Bos; A Fasano; J Rozing
Journal:  Diabetologia       Date:  2010-09-19       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.